Print Page      Close Window     

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
February 14, 2019
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
BUFFALO, N.Y., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release fourth quarter and fiscal year ended December 31, 2018 earnings results on March 11, 2019 before the market opens. The Company will host a conference call and live audio webcast on Monday, March 11, 2019, at 8:30 a... 
Printer Friendly Version 
February 04, 2019
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019 BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract reporting the results from two Phase III studies of KX2-391 Ointment in the treatment of actinic keratosis has b... 
Printer Friendly Version 
January 09, 2019
Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
BUFFALO, N.Y., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from the study is expected to be available in mid-2019. ... 
Printer Friendly Version 
January 03, 2019
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
Chongqing Jingdong Pharmaceutical strengthens its product portfolio of innovative drugs with novel small molecule KX2-391  Athenex further builds its presence in China, broadening global reach  Athenex to receive upfront and potential development milestones, along with tiered royalties based on net sales BUFFALO, N.Y., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization... 
Printer Friendly Version